logo-loader
RNS
Cello Health PLC

Cello Health PLC - Total Voting Rights

RNS Number : 3312T
Cello Health PLC
13 November 2019
 

13 November 2019

 

Cello Health plc

("Cello" or the "Company")

 

Total Voting Rights

 

As at 13 November 2019, Cello's issued share capital comprises 106,612,126 ordinary shares of 10 pence each ("Ordinary Shares"), of which 453,000 Ordinary Shares are held in treasury. The total number of current voting rights in the Company is therefore 106,159,126 Ordinary Shares.

 

The above figure (106,159,126 Ordinary Shares) may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

Enquiries:

 

Cello Health plc

020 7812 8460

Mark Scott, Chief Executive


Mark Bentley, Group Finance Director

www.cellohealthplc.com




Cenkos Securities plc

020 7397 8900

Giles Balleny


Harry Hargreaves




Buchanan

Mark Court

020 7466 5000

Jamie Hooper


Sophie Wills


 

 


About Cello Health plc

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise, differentiate their assets, and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.

For further information, please visit: https://cellohealthplc.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRQXLFFKFFXFBE
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read